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Abstract
Background: The association between vitamin D deficiency and obesity in healthy populations and different
disease states remains unsettled with studies reporting conflicting findings. Moreover, current dietary
recommendations for vitamin D do not take into account a person’s body mass index (BMI). We investigated the
relationship between serum 25-hydroxy-vitamin D [25(OH)D] and BMI in cancer.
Methods: A consecutive case series of 738 cancer patients. Serum 25(OH)D was measured at presentation to the
hospital. The cohort was divided into 4 BMI groups (underweight: <18.5, normal weight: 18.5-24.9, overweight: 25-
29.9, and obese: >30.0 kg/m
2). Mean 25(OH)D was compared across the 4 BMI groups using ANOVA. Linear
regression was used to quantify the relationship between BMI and 25(OH)D.
Results: 303 were males and 435 females. Mean age at diagnosis was 55.6 years. The mean BMI was 27.9 kg/m
2
and mean serum 25(OH)D was 21.9 ng/ml. Most common cancers were lung (134), breast (131), colorectal (97),
pancreas (86) and prostate (45). Obese patients had significantly lower serum 25(OH)D levels (17.9 ng/ml) as
compared to normal weight (24.6 ng/ml) and overweight (22.8 ng/ml) patients; p < 0.001. After adjusting for age,
every 1 kg/m
2 increase in BMI was significantly associated with 0.42 ng/ml decline in serum 25(OH)D levels.
Conclusions: Obese cancer patients (BMI >= 30 kg/m
2) had significantly lower levels of serum 25(OH)D as
compared to non-obese patients (BMI <30 kg/m
2). BMI should be taken into account when assessing a patient’s
vitamin D status and more aggressive vitamin D supplementation should be considered in obese cancer patients.
Background
Serum 25-hydroxyvitamin D [25(OH)D] is the major
circulating form of vitamin D and a standard indicator
of vitamin D status [1,2]. Several studies have described
an inverse relationship between serum 25(OH)D and
cancer risk [3-5]. The relationship between regular vita-
min D intake and reduced cancer incidence has also
been reported [6]. Furthermore, higher plasma 25(OH)D
levels are associated with improved survival in prostate
[7], breast [8], lung [9], colorectal [10] and ovarian [11]
cancers. A better vitamin D status at the time of diagno-
sis and treatment, adjusted for season of diagnosis, has
been shown to improve survival [12,13].
Several factors are involved in the regulation of 25
( O H ) Di n c l u d i n g :a g e ;g e n d e r[ 1 4 ] ;r a c e[ 1 5 ] ;d i e t a r y
intake [2]; season [16]; and sunlight exposure [17].
Recently, the relationship between obesity and vitamin
D status has been investigated suggesting decreased
bioavailability of 25(OH)D from cutaneous and dietary
sources in association with obesity [18]. Additional stu-
dies have investigated the relationship between obesity
and vitamin D levels. The results, however, are conflict-
ing with studies reporting either no relationship [19], or
an inversely proportional relationship [20-22] between
body mass index (BMI) and serum 25(OH)D.
In studies of obese adolescents in the United States,
vitamin D deficiency has been correlated with greater
weight and elevated BMI [23,24]. In the healthy adoles-
cent population the distribution of fat was found to be
associated with vitamin D status with obese adolescents
being found to have 25(OH)D deficiency [25]. Children
with a body weight, BMI, bicipital skin fold thickness,
waist measurement and waist/height ratio above the
50th percentile for each variable were found to be at a
greater risk of having a low serum 25(OH)D concentra-
tion [26]. Similarly, body weight, BMI, and waist cir-
cumference of healthy women with higher vitamin D
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low vitamin D levels [27]. A statistically significant nega-
tive correlation between BMI and serum 25(OH)D in
Caucasian and African Americans healthy adults has
also been described [28].
An inverse relationship between obesity and serum
levels of 25(OH)D has also been demonstrated in differ-
ent disease states. In children with epilepsy, female sex
and increased BMI were significant risk factors for low
vitamin D levels [29]. In patients with Systemic Lupus
Erythematosus, being overweight was found to be asso-
ciated with vitamin D deficiency [30]. In another study,
vitamin D deficiency was found to be more prevalent in
morbidly obese patients presenting with the metabolic
syndrome [31]. Finally, in women with polycystic ovar-
ian disease low serum 25(OH)D concentrations were
found as a result of obesity and insulin resistance [32].
The association between vitamin D and obesity
assumes even greater importance in cancer, given the
alleged role of both obesity and vitamin D in cancer risk
and survival. Although it has been recommended that
adiposity should be considered when assessing vitamin
D requirements in obese patients [33], current dietary
recommendations do not take into account a person’s
BMI and it remains unclear whether the dose of vitamin
D required for repletion is related to the degree of obe-
sity. And there are to date, no studies which indicate
whether the presence of malignant disease compounds
these issues. In the current study, we have addressed the
first aspect of this question by investigating the relation-
ship between serum 25(OH)D and BMI in a large and
diverse population of cancer patients at a comprehensive
cancer center.
Methods
Study Sample
This was a cross-sectional study performed on a consecu-
tive case series of 738 cancer patients treated at Cancer
Treatment Centers of America
® (CTCA) at Midwestern
Regional Medical Center (MRMC) between January 2008
and June 2008. Only patients with a histologically con-
firmed diagnosis of cancer were included. The study
examined the serum 25(OH)D levels of all new patients
presenting to our institution as part of a routine nutri-
tional status screening prior to initiation of anticancer
therapy. The study did not restrict patients with respect
to treatment history, tumor histology or stage. This study
was approved by the Institutional Review Board at Mid-
western Regional Medical Center (MRMC).
Vitamin D Assessment
All patients underwent a baseline serum 25(OH)D
assessment before undergoing any treatment at our hos-
pital. Serum was collected, packed in coolpacks and sent
to the Laboratory Corporation of America (Raleigh, NC)
where a chemiluminescence immune assay (CLIA, Dia-
Sorin Liasion assay) was used to measure 25(OH)D.
Serum samples were incubated with antivitamin-D
coated microparticles and isoluminol derivative-conju-
gated 25(OH)D before measurement of chemilumines-
cent signals. Analysis was completed within 48 hours of
collection. The DiaSorin Liasion 25(OH)D assay has
been clinically validated to be comparable in accuracy
and precision to the radioimmunoassay (RIA). This
method uses the same particles used in the DiaSorin
RIA technique. Studies have found this to be a rapid,
accurate, and precise tool for the measurement of serum
25(OH)D [34,35].
BMI Assessment
At the subjects’ first visit, measurement of height and
weight were performed. The subjects wore light clothing
and no shoes. BMI was calculated as weight (kg)/
squared height (m
2).
Data Analysis and Statistical Methods
BMI was the independent variable and used as both con-
tinuous and categorical variables. Serum 25(OH)D was
the dependent variable. Age at diagnosis and gender were
used as covariates. Correlations between 25(OH)D and
BMI as well as 25(OH)D and age were evaluated using
Spearman’s rho non-parametric correlation coefficient
owing to their non-normal distributions. BMI was divided
into 4 groups according to WHO criteria: <18.5 kg/m
2
(underweight), 18.5-24.9 kg/m
2 (normal weight), 25-29.9
kg/m
2 (overweight), and >30.0 kg/m
2 (obese). Mean 25
(OH)D was compared across the 4 BMI groups using
Analysis of Variance (ANOVA). Mean 25(OH)D levels
were compared between males and females using 2 sam-
ple t-test. For the purpose of further exploring the rela-
tionship between BMI and serum 25(OH)D, we
dichotomized 25(OH)D into 2 groups using a cut-off of
32 ng/ml. Patients with serum levels of <32 ng/ml were
considered to have suboptimal serum 25(OH)D levels.
Using chi square tests, we investigated the relationship
between categorical BMI and dichotomous serum 25
(OH)D. Univariate and multivariate linear regression ana-
lyses were used to quantify the relationship between BMI
and 25(OH)D. Age, BMI and serum 25(OH)D were used
as continuous variables for the purpose of regression ana-
lyses. All data were analyzed using SPSS 17.0 (SPSS Inc.,
Chicago, IL, USA). All analyses were two-tailed, and p
values were considered significant when < 0.05.
Results
Baseline Characteristics
Table 1 describes the baseline characteristics of our
patient cohort. The most common cancer types were
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ian age at presentation was 56 years (range 25 - 94
years). The mean BMI was 27.9 kg/m
2 (SD = 6.7 kg/
m
2). The mean serum 25(OH)D was 21.9 ng/ml (SD =
13.5 ng/ml).
Univariate Analysis
The Spearman’s rho correlation coefficient for BMI-25
(OH)D association was -0.20 (p < 0.001) and for age-25
(OH)D association was 0.1 (p = 0.009). Table 2 com-
pares mean serum 25(OH)D levels across the 4 cate-
gories of BMI using ANOVA. Obese patients (>30.0 kg/
m
2) had statistically significantly lower serum 25(OH)D
levels as compared to normal weight (18.5-24.9 kg/m
2)
and overweight (25-29.9 kg/m
2) patients. Using 2 sample
t-test, there was no significant difference found between
mean 25(OH)D levels in males (21.8 ng.ml) and females
(22 ng/ml); p = 0.83). Table 3 compares the prevalence
of suboptimal serum vitamin D (<32 ng/ml) across the 4
categories of BMI. Obese patients had the highest preva-
lence of suboptimal vitamin D status. Table 4 provides
the results of univariate linear regression analyses for
age and BMI. Every 1 kg/m
2 increase in BMI was
significantly associated with 0.43 ng/ml decline in serum
25(OH)D levels. Also, every one year increase in age at
diagnosis was significantly associated with 0.11 ng/ml
increase in serum 25(OH)D levels. It was decided to
control for age in multivariate analysis.
Multivariate Analysis
Table 5 displays the results of multivariate regression
analysis for BMI-25(OH)D association after controlling
for the effects of age at diagnosis. Every 1 kg/m
2
increase in BMI was significantly associated with 0.42
ng/ml decline in serum 25(OH)D levels after adjusting
for age. Age was no longer significant in the final model.
The BMI-25(OH)D association was further explored in
each of the top 5 cancer sites including lung, breast, col-
orectal, pancreas and prostate. A statistically significant
relationship was observed in breast and colorectal can-
cers only. After adjusting for age, every 1 kg/m
2 increase
in BMI was significantly associated with 0.51 ng/ml (p =
0.02) and 0.46 ng/ml (p = 0.006) decline in serum 25
(OH)D levels in breast and colorectal cancers
respectively.
Discussion
Characterization of serum vitamin D levels in cancer
patients is of considerable importance given the role of
vitamin D in influencing cancer risk and survival. An
important question that arises when recommending
vitamin D supplementation in deficient cancer patients
is whether the dose should be adjusted according to a
patient’s BMI. While there is some evidence in the lit-
erature documenting an inverse relationship between
BMI and serum 25(OH)D in healthy and diseased popu-
lations, this relationship in cancer has never been
Table 1 Baseline patient characteristics (N = 738)
Characteristic Categories Number Percent (%)
Gender Males 303 41.1
Females 435 58.9
Age at Presentation (years) Mean 55.6
Median 56.0
Range 25 - 94
Cancer Site Lung 134 18.2
Breast 131 17.8
Colorectal 97 13.1
Pancreas 86 11.7
Prostate 45 6.1
Others 245 33.2
BMI Categories (kg/m
2) <18.5 23 3.1
18.5 - 24.9 239 32.4
25 - 29.9 249 33.7
>= 30 227 30.8
Table 2 Mean serum 25(OH)D across 4 categories of BMI
- univariate analysis (N = 738)
BMI (kg/m
2) Mean 25(OH)D
(SD)
95% CI ANOVA
(P-Value)
1) < 18.5 22.4 (12.9) 16.8-28.1 10.5 (p < 0.001)
2) 18.5 to 24.9 24.6 (15.9) 22.6-26.7
3) 25 to 29.99 22.8 (12.6) 21.2-24.4
4) >= 30 17.9 (10.6) 16.6-19.4
Post-hoc tests revealed significant differences between 2 and 4 &3 and 4 BMI
categories
Table 3 Relationship between categorical BMI and
dichotomous serum 25(OH)D (N = 738)
BMI (kg/m
2) Suboptimal
25(OH)D
<32 ng/ml
Optimal 25(OH)D
>= 32 ng/ml
Chi Square
(P-Value)
< 18.5 18 (78.3) 5 (21.7)
18.5 to 24.9 177 (74.1) 62 (25.9) 21.2 (p < 0.001)
25 to 29.99 206 (82.7) 43 (17.3)
>= 30 205 (90.3) 22 (9.7)
The numbers in parenthesis are row percentages
Table 4 Univariate linear regression analysis with serum
25(OH)D as the dependent variable (N = 738)
Variable B Coefficient
(Standard Error)
95% CI P - Value
BMI -0.43 (0.07) -0.57 to -0.29 <0.001
Age 0.11 (0.05) 0.009 to 0.20 0.03
Gender (male as reference) 0.22 (1.0) -1.8 to 2.2 0.83
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investigate this relationship. The results demonstrate
that serum 25(OH)D levels are significantly lower in
obese cancer patients as compared to normal and over-
weight patients, and that every unit increase in BMI is
associated with a corresponding decrease in serum 25
(OH)D that is statistically significant.
Multiple mechanisms have been proposed to explain
the association of obesity with hypovitaminosis D,
including lack of sunlight exposure from physical inac-
tivity [36] and sequestration of vitamin D in subcuta-
neous fat depots [33]. Wortsman et al. reported that the
capacity of the skin to produce vitamin D is not altered
in obesity. However, the increase in serum vitamin D
after sun exposure was 57% less in obese compared with
non-obese subjects suggesting a decreased bioavailability
of vitamin D because of its deposition in body fat com-
partments, given that vitamin D is fat soluble [18].
Young KA et al. observed that higher BMI and subcuta-
neous adipose tissue were associated with lower 1,25-
dihydroxyvitamin D [1,25[OH]2D], after controlling for
25[OH]D levels, suggesting a more complex relationship
between vitamin D and adiposity than simply attributing
this association to vitamin D bioavailability [37].
Another hypothesis suggests a negative feedback inhibi-
tion of 25(OH)D synthesis in liver by the increased level
of 1,25(OH)2D [32,38]. Bell NH et al. reported that
alteration of the vitamin D endocrine system in obese
subjects is characterized by secondary hyperparathyroid-
ism which is associated with enhanced renal tubular
reabsorption of calcium and increased circulating 1,25
(OH)2D which causes a feedback inhibition of 25(OH)D
synthesis [39]. However, some recent studies have
reported an inverse correlation between BMI and serum
1,25(OH)2D, casting a doubt on the hypothesis of nega-
tive feedback inhibition [21,28].
There are obvious clinical implications of this work
such as the need to monitor the vitamin D intake and
serum 25(OH)D levels in patients with cancer and sup-
plementation of vitamin D in those who are found to
have suboptimal levels. In our recently published study
in a sample of 799 cancer patients, we found that
patients with suboptimal vitamin D levels at baseline,
when supplemented with 8000 IU of Vitamin D3 (four
2000 IU D3 capsules) daily as part of their nutritional
care plan, showed significant improvement in their
serum vitamin D levels after a mean follow-up of 14.7
weeks [40]. A study conducted by Lee P et al. in 95 out-
patients found that increments of vitamin D level were
less in obese individuals, implying that a larger dose of
vitamin D supplementation is required for repletion
compared with normal-weight individuals [33]. Similarly,
Jorde et al. investigated the serum 25(OH)D response to
vitamin D supplementation in relation to BMI and con-
cluded that when giving vitamin D supplements to the
very obese, the dose has to be higher than in the lean
subjects if the same serum 25(OH)D levels are to be
achieved [41]. A study conducted in postmenopausal
women by Moschonis G et al. suggested a need for
higher daily vitamin D intake in obese than in thinner
individuals to compensate for the lower bioavailability of
endogenously produced cholecalciferol [42]. Blum M et
al. found that change in 25(OH)D levels in response to
vitamin D supplementation was inversely associated
with BMI in healthy men and women 65 years of age
and older. As a result, they recommend that that body
size should be taken into account when estimating the
amount of vitamin D intake needed to raise 25(OH)D to
the desired level [43]. The most recent report by the
Institute of Medicine recommends a dietary reference
intake of 600 IU for vitamin D [44]. The results of our
study, coupled with the findings reported by other
researchers as described above, provide preliminary evi-
dence to suggest that obese people might require a
higher dose of vitamin D to achieve optimal serum
levels.
Interestingly, we found a weak but significantly posi-
tive association between age and 25(OH)D levels. This
is unexpected since the efficiency of the photosynthesis
o fv i t a m i nDi nh u m a ns k i nd e c r e a s e sw i t ha g e[ 4 5 ] .I n
addition, older people may receive less sunlight expo-
sure because of frailty and reduced exercise levels or for
cultural and behavioral reasons [46]. The literature in
this regard is inconsistent with reports being presented
purporting to demonstrate a positive relationship
[45,47], no relationship [48], and an inverse relationship
[49,50] between age and 25(OH)D level. Although it is
reasonable to postulate that differences in life style and
dietary habits will explain these inconsistencies, the rea-
son for these divergent results remains unclear and war-
rants rigorously controlled studies.
Our study has some limitations. This study, because of
its retrospective nature, relies on data not primarily
meant for research. As a result, we could not adjust for
several potential confounding factors that could have
influenced serum 25(OH)D levels. For example, we did
not adjust for season of blood draw in our analyses.
However, our analysis was limited to patients tested in
late winter, spring and early summer, so a major differ-
ence in sun exposure seems unlikely to account for the
Table 5 Multivariate linear regression analysis with
serum 25(OH)D as the dependent variable (N = 738)
Variable B Coefficient
(Standard Error)
95% CI P - Value
BMI -0.42 (0.07) -0.56 to -0.28 <0.001
Age 0.08 (0.05) -0.009 to 0.18 0.08
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population. We included only one serum sample from
each subject. Intervention and interpretation of serum
25(OH)D levels might require multiple measurements
over a period of time. Moreover, we did not have infor-
mation on intake of vitamin D or data regarding their
typical sun exposure which could have shed further
light on the subjects’ vitamin D status.
Other variables such as race, physical activity and can-
cer treatment history are all thought to affect 25(OH)D
status but were not controlled for in the analyses.
Because anthropometric indicators of adiposity such as
BMI are traditionally weaker than direct measures of
adiposity, it is likely that we are underestimating the
association between vitamin D and overall adiposity by
using BMI as a measure of obesity [37]. However, BMI
is non-invasive, low cost and east to perform. Despite
t h e s el i m i t a t i o n s ,o u rs t u d yp r o v i d e se v i d e n c eo fa n
inverse relationship between serum vitamin D and BMI
in cancer patients - a novel finding in the oncology
patient population. Strengths of the present investigation
are its relatively large sample size and the fact that the
vitamin D analyses were all performed using the same
assay.
The results of this study suggest several areas for
future research. Paramount among these is the immedi-
ate need to determine the response to vitamin D supple-
mentation in cohorts of patients segregated according to
BMI or other measures of obesity. Such studies are well
within the capacity of clinical investigators and are criti-
cal to establishing optimal vitamin D dose and schedules
for adequate repletion. The results of such studies
should support further investigation of the consequences
of vitamin D repletion on clinical outcomes in cancer
patients pertinent to either specific functions (e.g. treat-
ment response, wound healing) or more general out-
comes such as prognosis and QoL. Ultimately, such
studies should determine whether restoration and main-
tenance of adequate vitamin D levels can influence
tumor control and survival. Although the current study
was conducted in a large heterogeneous cancer popula-
tion, the same approaches would be appropriate for elu-
cidating the importance of vitamin D levels in
homogeneous patient populations segregated according
to tumor type and treatment selection.
Conclusions
We found that obese cancer patients (BMI >= 30 kg/m
2)
had significantly lower levels of serum 25(OH)D as com-
pared to non-obese patients (BMI <30 kg/m
2). BMI
should be taken into account when assessing a patient’s
vitamin D status and more aggressive vitamin D supple-
mentation should be considered in obese cancer patients.
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